Lupin receives US FDA clearance for Nagpur injectable facility

Lupin Limited (BSE: 500257) announced today that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India. The clearance covers the manufacturing of drug-medical device combination products. The US FDA issued the EIR following its inspection of the facility, which took place between June 10 and June 13, 2024. According to Nilesh Gupta, Managing Director of Lupin, the company remains committed to producing complex generic and essential products that address unmet needs. Lupin is a global pharmaceutical company headquartered in Mumbai.